MSD and Daiichi Sankyo have announced first subject dosing in the randomised IDeate-Prostate01 Phase III trial of ifinatamab ...

Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial ...

We describe here a newly identified member of the human B7 family, designated B7 homolog 3 (B7-H3), that shares 20–27% amino acid identity with other B7 family members. B7-H3 mRNA is not ...

Download Report: https://www.kuickresearch.com/report-cd276-antibody-cd276-inhibitor-b7-h3-inhibitor-cd276-receptor-cd276-marker-cd276-cancer Antibodies have become a ...

Post the identification of immune checkpoints, research studies were focused on identifying more immune checkpoints and the B7-H3 was one of those discovered in the early 2000s. The protein has ...

Results of a Phase 1/2 Study of MHB088C: a Novel B7-H3 Antibody-Drug Conjugate (ADC) Incorporating a Potent DNA Topoisomerase I Inhibitor in Recurrent or Metastatic Solid Tumors In this Phase 1/2 ...

BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint Highly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer ...

Increased expression of B7-H3 has been previously reported in multiple solid tumors, including pancreatic cancer. In a recent article, researchers from the University of Tuebingen discussed the ...

GSK’227 is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. The Food and Drug Administration (FDA ...

The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic ...